Knowledge In Numbers: Pairing Digital Pathology with Integrated Biostatistics

Posted on Tue/30/JulyTue/30/July by AZBio

Rapid changes in the pharmaceutical industry and in the discipline of pathology expand the need for biostatisticsContinue reading→

State of Biomedical Innovation – Global Leaders share ideas at Brookings

Posted on Sat/20/JulySat/20/July by AZBio

On July 16, the Engelberg Center for Health Care Reform at Brookings hosted the second annual State of Biomedical Innovation conference.Continue reading→

DxNA LLC and PathoGene LLC complete Staph MRSA+ Assay License Agreement and Sign Letter of Intent for Acquisition

Posted on Wed/17/JulyWed/17/July by AZBio

Saint George, UT, July 17, 2013Continue reading→

BioPharm Insight Analysis: Ulthera

Posted on Mon/15/JulyMon/15/July by AZBio

Ulthera evaluating exit strategies in wake of turning cash-flow positive – CEO BioPharm InsightContinue reading→

Iron Horse Diagnostics partnership for ALS diagnostics on the horizon

Posted on Fri/12/JulyFri/12/July by AZBio

Iron Horse Diagnostics partnership for ALS diagnostics on the horizon, raising USD 4m for TBI program

Two 250-patient TBI trials planned for when funding is in place
ALS diagnostics validation process to be complete in four months
Seeking CRO for ALS, and eventually TBI, diagnostics trialsContinue reading→

MSDx Welcomes David McCaleb to its Board of Directors

Posted on Thu/11/JulyThu/11/July by AZBio

MSDx, Inc., announced today that David McCaleb has joined its Board of Directors. With over thirty years of experience in leading pharmaceutical companies and biotech start-ups, his successful track record in commercialization and fundraising will augment the MSDx team. Continue reading→

Calimmune Initiates HIV Stem Cell Study at Two California Research Sites

Posted on Tue/9/JulyTue/9/July by AZBio

The HIV gene medicines company, Calimmune, announced today that the first patient has begun treatment in a Phase I/II clinical trial designed to determine whether a pioneering genetic medicine approach can help to protect individuals infected with HIV from the effects of the virus. The study, “Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection,” utilizes a gene medicine called Cal-1, developed in the lab of Nobel Laureate Dr. David Baltimore and by Calimmune.Continue reading→